Abstract
The presented review describes a clinical case of a comorbid patient type 2 diabetes mellitus (T2DM), the severity of whose disease was due to the presence of COVID-19 infection suffered on the eve of hospitalization, as well as the presence of concomitant diseases from the cardiovascular and nervous systems. In the aggregate of simultaneously occurring pathological processes, a patient with type 2 diabetes had a picture of uncontrolled hyperglycemia. The lifeline for the comorbid patient was orientation towards a more effective triple combined hypoglycemic therapy consisting of a type 2 sodium-glucose cotransporter 2 inhibitor, a medcine from the aGLP-1 group and metformin.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
